CClinicalTrials.gg
Status unknownNCT03764956Updated Sep 10, 2019

Comparison of Efficacy of LGIT and MAD Among Children With Drug Resistant Epilepsy

A Phase 4 interventional study of Low glycemic Index Therapy (LGIT) and Modified Atkins Diet (MAD) in Drug Resistant Epilepsy and Ketogenic Dieting, sponsored by All India Institute of Medical Sciences, New Delhi. Status unknown at 2 sites in India. Open to participants aged 1 Year to 15 Years. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by All India Institute of Medical Sciences, New Delhi · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
1 Year to 15 Years
Sex
All
01

Study summary

To compare the efficacy of two less restrictive dietary therapies - LGIT and MAD, used for treatment of drug resistant epilepsy in children

Read the detailed description

Up to one third of patients with epilepsy progress to drug resistant epilepsy (DRE). Current treatment options for DRE include epileptic surgery and dietary therapy. Classic KD (Ketogenic diet) is the most studied dietary therapy but the stringent restrictions and practical difficulty makes it difficult to follow. So less restrictive diets like MAD and LGIT were introduced. These are reported to have less adverse effects also. But no published study has ever been conducted comparing these two diets head to head.

02

Conditions studied

  • Drug Resistant Epilepsy
  • Ketogenic Dieting

Keywords

  • MAD
  • LGIT
03

In context

Epilepsy

1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.

This study's planned enrollment of 110 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

All India Institute of Medical Sciences, New Delhi is the lead sponsor of 146 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children aged 1-15 years with drug resistant epilepsy
  • Willing to come for regular follow-up according to study protocol Drug resistant epilepsy defined as
  • Seizure frequency >4 seizures per month, while on optimal doses of at least 2 prescribed antiepileptic drugs
  • For West syndrome, drug resistant epilepsy will be defined as more than 4 clusters of spasms per month despite treatment with antiepileptic drugs and either ACTH(Adrenocorticotrophic hormone) or Vigabatrin

Exclusion criteria

Exclusion Criteria:

  • Surgically remediable causes for DRE
  • Inborn errors of metabolism
  • Previously received KD, MAD or LGIT
  • Known case of

    1. Chronic kidney disease
    2. Chronic liver disease/GI illness
    3. Congenital/acquired heart disease
    4. Chronic respiratory illness
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Low Glycemic Index therapy

    Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only

    Other: Low glycemic Index Therapy (LGIT)

  • Active comparator
    Modified Atkins Diet

    Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio

    Other: Modified Atkins Diet (MAD)

Interventions

  • OtherLow glycemic Index Therapy (LGIT)

    Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.

  • OtherModified Atkins Diet (MAD)

    Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.

06

What researchers measure

Primary outcomes

  1. Percentage of seizure reduction from baseline at 24 weeks of therapy

    Mean weekly seizure reduction at 24 weeks divided by Mean weekly seizure measured at baseline multiplied by 100

    Time frame: At the end of 24 weeks of dietary therapy

Secondary outcomes

  1. Proportion of children who achieve >50% seizure reduction

    Number of children with \>50% reduction divided by number of children in each arm

    Time frame: At the end of 24 weeks of dietary therapy

  2. Incidence of adverse events

    Routine hemogram, Renal function test (RFT), Liver function test (LFT) and lipid profile will be assessed for any alterations. Adverse events, vomiting, constipation and diarrhea will be checked by parents record

    Time frame: At the end of 24 weeks of dietary therapy

  3. Compliance of participants with dietary therapy in each arm will be determined each week, whether satisfactory or unsatisfactory

    Weekly compliance assessment of each participant will be done

    Time frame: At the end of 24 weeks of dietary therapy

  4. Change in Social quotient(SQ) with each dietary therapies

    Proportion of children with improvement in Social quotient (SQ) assessed by Vineland Social Maturity Scale (VSMS) at 24 weeks. VSMS consists of 8 subsets - Communication skills, General self-help ability, Locomotion skills, Occupation skills, Self-direction, Self-help eating, Self-help dressing, Socialization skills. Social age is calculated by adding the scores of all subsets. Social quotient (SQ) is calculated by social age divided by chronological age multiplied by 100.

    Time frame: At the end of 24 weeks of dietary therapy

  5. Change in Quality of Life of participants who are less than 4 years of age at 24 weeks as compared to baseline

    In children less than 4 years quality of life is assessed by PedsQL (Pediatric Quality of life inventory). PedsQL consists of 21 questions each having 5 responses with scores 0,1,2,3 and 4. Minimum score is 0 and maximum is 84. Quality of life is poor with larger score.

    Time frame: At the end of 24 weeks of dietary therapy

  6. Change in Quality of Life of participants who are more than or equal to 4 years of age at 24 weeks as compared to baseline

    In children with age 4 years or more, QOLCE 55 (Quality of life in childhood epilepsy questionnaire) is used to assess quality of life. QOLCE 55 consists of 55 questions which are classified into 4 categories. Each question have 5 responses with scores as 0,25,50,75 and 100. Mean score of each category is calculated and final score calculated by mean of the scores of 4 categories. Minimum score is 0 and maximum is 100. Quality of life is better with larger score.

    Time frame: At the end of 24 weeks of dietary therapy

  7. Change in Quality of Life of caregivers at 24 weeks as compared to baseline

    Quality of life of caregivers is assessed by WHOQOL-BREF. WHOQOL BREF contains 26 items categorized into 4 domains. For each question response is scored 1,2,3,4 or 5. Total raw score is then calculated and is converted to transformed score. Minimum score is 0 and maximum is 100. Quality of life is poor with smaller score.

    Time frame: At the end of 24 weeks of dietary therapy

  8. Gut microbiota (GM) analysis pre and post dietary therapy

    Changes in percentage distribution of various micro organisms in gut microbiota after dietary therapy as compared to baseline GM

    Time frame: At the end of 24 weeks of dietary therapy

  9. Change in behavioral abnormalities with each dietary therapy

    Behavior assessment is done using Child behavior check list (CBCL).This questionnaire contains 100 and 113 questions for age groups of 1 ½ - 5 years and 6-18 years respectively. Score of 2 will be given for a response of 'very true', 1 for a response of 'somewhat true' and 0 for 'not true'. Total score is obtained by adding all the subsets. Subsets for age 1.5 years to 5 years include - Emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior and other problems. Subsets for age 6 years to 12 years include - Anxious/Depressed, withdrawn, somatic complaints, social problems, thought problems, attention problems, rule breaking behavior, aggressive behavior, other problems. Raw score is then converted to T score according to the published charts. Minimum T score is 28 and maximum is 100. Larger score indicates more behavioral problems.

    Time frame: At the end of 24 weeks of dietary therapy

07

Study locations

2 of 2 sites recruiting
  • All India Institute of Medical Sciences
    New Delhi, Delhi 110029, India
    Recruiting
  • AIIMS
    New Delhi, Delhi, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03764956
Lead sponsor
All India Institute of Medical Sciences, New Delhi
Responsible party
Sheffali Gulati (Professor, Chief, Child Neurology Division, All India Institute of Medical Sciences, New Delhi) — Principal investigator
First posted
Dec 5, 2018
Start date
Dec 26, 2018
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Sep 10, 2019

Study contacts

Sheffali Gulati, MD
Contact
sheffaligulati@gmail.com
9810386847
Vaishakh Anand, MD
Contact
drvyshakhanandmp@gmail.com
7838528549
Sheffali Gulati, MD
principal investigator · All India Institute of Medical Sciences, New Delhi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion